BMS Applies In Japan For Two-Pill Hepatitis C Therapy
This article was originally published in PharmAsia News
Executive Summary
Bristol-Myers Squibb has applied for Japan approval of its injection-free drug for hepatitis C, now known as BMS-790052 (daclatasvir), making Japan likely to be the first to get the medicine next year.